
1. Bioorg Med Chem Lett. 2017 Aug 1;27(15):3353-3358. doi:
10.1016/j.bmcl.2017.06.009. Epub 2017 Jun 3.

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA
gyrase and topoisomerase IV.

Mitton-Fry MJ(1), Brickner SJ(2), Hamel JC(2), Barham R(2), Brennan L(2),
Casavant JM(2), Ding X(2), Finegan S(2), Hardink J(2), Hoang T(2), Huband MD(2), 
Maloney M(2), Marfat A(2), McCurdy SP(2), McLeod D(2), Subramanyam C(2), Plotkin 
M(2), Reilly U(2), Schafer J(2), Stone GG(2), Uccello DP(2), Wisialowski T(2),
Yoon K(2), Zaniewski R(2), Zook C(2).

Author information: 
(1)Pfizer Worldwide Research and Development, Groton, CT 06340, USA. Electronic
address: mitton-fry.1@osu.edu.
(2)Pfizer Worldwide Research and Development, Groton, CT 06340, USA.

Novel (non-fluoroquinolone) inhibitors of bacterial type II topoisomerases
(NBTIs) are an emerging class of antibacterial agents. We report an optimized
series of cyclobutylaryl-substituted NBTIs. Compound 14 demonstrated excellent
activity both in vitro (S. aureus MIC90=0.125μg/mL) and in vivo (systemic and
tissue infections). Enhanced inhibition of Topoisomerase IV correlated with
improved activity in S. aureus strains with mutations conferring resistance to
NBTIs. Compound 14 also displayed an improved hERG IC50 of 85.9μM and a favorable
profile in the anesthetized guinea pig model.

Copyright © 2017 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.bmcl.2017.06.009 
PMID: 28610977  [Indexed for MEDLINE]

